# EDGAR Filing Document

**Accession Number:** 0001653087
**File Stem:** 0001193125-26-274130
**Filing Date:** 2026-6
**Character Count:** 6217
**Document Hash:** 124d1650be49db2925e3dbe4322c8a71
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-274130.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001193125-26-274130

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alector, Inc.
- **CENTRAL INDEX KEY:** 0001653087
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822933343
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38792
- **FILM NUMBER:** 261098311

**BUSINESS ADDRESS:**
- **STREET 1:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-231-5660

**MAIL ADDRESS:**
- **STREET 1:** 131 OYSTER POINT BLVD., SUITE 600
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alector LLC
- **DATE OF NAME CHANGE:** 20150915

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 17, 2026<br>

------

Alector, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-38792 | 82-2933343 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 131 Oyster Point Blvd.<br>Suite 600 |  |  |
| South San Francisco**,** California |  | 94080 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (415) 231-5660<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock | ALEC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 17, 2026, Alector, Inc. ("Alector") held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, Alector's stockholders voted on three proposals, each of which is described in more detail in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2026. The following is a brief description of each matter voted on and the certified results, including the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter.

1. The Class II director nominees were elected to serve until Alector's 2029 annual meeting of stockholders and until their successors are elected and qualified. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Director Name** | &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Withheld** | &nbsp;&nbsp;**Broker Non-Vote** |
| &nbsp;&nbsp;Elizabeth Garofalo, M.D. | &nbsp;&nbsp;60256636 | &nbsp;&nbsp;899318 | &nbsp;&nbsp;36697144 |
| &nbsp;&nbsp;Errol De Souza, Ph.D. | &nbsp;&nbsp;60461939 | &nbsp;&nbsp;694016 | &nbsp;&nbsp;36697144 |
| &nbsp;&nbsp;Kristine Yaffe, M.D. | &nbsp;&nbsp;45733503 | &nbsp;&nbsp;15422452 | &nbsp;&nbsp;36697144 |

---

2. Stockholders ratified the appointment of Ernst & Young LLP as Alector's independent registered accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Vote** |
| &nbsp;&nbsp;97,717,750 | &nbsp;&nbsp;52,302 | &nbsp;&nbsp;83,047 | &nbsp;&nbsp;0 |

---

3. Stockholders approved, on a non-binding advisory basis, the compensation of Alector's named executive officers as disclosed in the proxy statement for the Annual Meeting, known as the Say-on-Pay vote. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Vote** |
| &nbsp;&nbsp;58,652,335 | &nbsp;&nbsp;2,492,538 | &nbsp;&nbsp;11,082 | &nbsp;&nbsp;36,697,144 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Alector, Inc.** |
| Date: | June 17, 2026 | By:  | /s/Arnon Rosenthal |
|  |  |  | Arnon Rosenthal, Ph.D.<br>Co-Founder and Chief Executive Officer |

---

------